SAB Biotherapeutics Inc. (SABS)
undefined
undefined%
At close: undefined
4.08
1.24%
After-hours Dec 13, 2024, 04:00 PM EST

Cashflow (Annual)

Get detailed ratio statement breakdowns, uncovering price to free cash flow ratio, price per earnings, and much more.
Year FY23 FY22 FY21 FY20 FY19
Net Income -42.19M -17.14M -17.14M 20.12M -8.99M
Depreciation & Amortization 3.75M 1.65M 1.65M 548.18K 323.41K
Stock-Based Compensation 2.42M 2.67M 2.31M 1.30M 371.39K
Other Working Capital -528.64K 3.83M 3.83M 100.00K 84.50K
Other Non-Cash Items 8.58M 3.48M 3.48M -2 1.00
Deferred Income Tax - - - -2.25K 421.00
Change in Working Capital 2.33M 13.45M 13.45M -11.95M -923.37K
Operating Cash Flow -25.12M 3.76M 3.76M 10.00M -9.21M
Capital Expenditures -197.15K -10.94M -10.94M -12.73M -608.75K
Acquisitions - 76.39K - 9.00K -
Purchase of Investments - - - - -
Sales Maturities Of Investments - - - - -
Other Investing Acitivies 44.45K -76.39K -10.94M - -
Investing Cash Flow -152.70K -10.94M -10.94M -12.72M -608.75K
Debt Repayment -390.44K -1.19M 1.54M -917.88K -
Common Stock Repurchased - -5.52M - - -
Dividend Paid - - - - -
Other Financial Acitivies 67.16M 76.97K 32.58M 9.90M -
Financial Cash Flow 66.77M 34.12M 34.12M 8.98M 3.68M
Net Cash Flow 41.52M 26.93M 26.93M 6.26M -6.14M
Free Cash Flow -25.32M -7.19M -7.19M -2.73M -9.82M